|
Market Closed -
Nasdaq
16:00:00 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 0.3119 USD | -6.48% |
|
-2.65% | -68.81% |
| 09-02 | Needham Downgrades TScan Therapeutics to Hold From Buy | MT |
| 09-02 | Wedbush Downgrades TScan Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $5 | MT |
Company Valuation: TScan Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 106.9 | 37.32 | 278.8 | 171.8 | 56.75 | 21.14 | - | - |
| Change | - | -65.09% | 647.03% | -38.39% | -66.96% | -62.75% | - | - |
| Enterprise Value (EV) 1 | -54.48 | -53.41 | 116.8 | -86.26 | -63.12 | -77.73 | -53.62 | -16.01 |
| Change | - | 1.96% | 318.71% | -173.84% | 26.82% | -23.13% | 31.02% | 70.14% |
| P/E | -1.08x | -0.56x | -4.29x | -2.67x | -1x | -0.39x | -0.52x | -0.54x |
| PBR | - | 0.37x | 1.85x | 0.71x | 0.46x | 0.23x | 0.37x | 0.53x |
| PEG | - | 0x | 0.1x | 0.2x | 0.1x | 0x | 0x | 0.16x |
| Capitalization / Revenue | 10.5x | 2.76x | 13.2x | 61x | 5.5x | 4.69x | 6.45x | 1.12x |
| EV / Revenue | -5.37x | -3.95x | 5.55x | -30.6x | -6.11x | -17.3x | -16.4x | -0.85x |
| EV / EBITDA | 1.27x | 0.94x | -1.41x | 0.71x | 0.52x | 0.59x | 0.38x | 0.13x |
| EV / EBIT | 1.12x | 0.8x | -1.25x | 0.64x | 0.46x | 0.73x | 0.7x | 0.18x |
| EV / FCF | 0.93x | 0.76x | -1.81x | 0.75x | 0.45x | 1.38x | 1.39x | 0.46x |
| FCF Yield | 108% | 132% | -55.2% | 133% | 221% | 72.5% | 72.2% | 216% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -4.17 | -2.75 | -1.36 | -1.14 | -1 | -0.805 | -0.6 | -0.58 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10.14 | 13.54 | 21.05 | 2.816 | 10.32 | 4.505 | 3.277 | 18.92 |
| EBITDA 1 | -42.8 | -56.95 | -82.89 | -121.2 | -121.2 | -130.8 | -140.2 | -126.8 |
| EBIT 1 | -48.64 | -66.64 | -93.46 | -134.8 | -135.8 | -106.5 | -77.07 | -87.79 |
| Net income 1 | -48.62 | -66.22 | -89.22 | -127.5 | -129.8 | -104.9 | -79.1 | -86.94 |
| Net Debt 1 | -161.4 | -90.74 | -162 | -258 | -119.9 | -98.87 | -74.76 | -37.15 |
| Reference price 2 | 4.5000 | 1.5500 | 5.8300 | 3.0400 | 1.0000 | 0.3119 | 0.3119 | 0.3119 |
| Nbr of stocks (in thousands) | 23,761 | 24,080 | 47,825 | 56,505 | 56,748 | 67,779 | - | - |
| Announcement Date | 3/9/22 | 3/8/23 | 3/6/24 | 3/5/25 | 3/4/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.41x | -16.93x | 0.58x | - | 22.6M | |
| 20.84x | 7.34x | 14.75x | 1.42% | 70.89B | |
| 32.38x | 9.35x | 45.22x | 0.04% | 62.32B | |
| -75.68x | 14.64x | -70.6x | -.--% | 27.07B | |
| 30.31x | 6.44x | 16.73x | -.--% | 26.2B | |
| -15.08x | 5.66x | -7.11x | -.--% | 24.78B | |
| 28.05x | 5.3x | 17.61x | -.--% | 20.59B | |
| 45.07x | 16.55x | 33.56x | 0.33% | 15.52B | |
| 18.07x | 5.39x | 12.58x | -.--% | 14.49B | |
| -15.33x | 3461.53x | -17.7x | -.--% | 14.14B | |
| Average | 6.82x | 351.53x | 4.56x | 0.2% | 27.6B | |
| Weighted average by Cap. | 11.56x | 185.42x | 10.98x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TCRX Stock
- Valuation TScan Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
